What is HC Wainwright’s Forecast for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of FibroGen in a report released on Tuesday, March 18th. HC Wainwright analyst M. Keller expects that the biopharmaceutical company will post earnings of $0.04 per share for the quarter. HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. HC Wainwright also issued estimates for FibroGen’s Q2 2025 earnings at $0.05 EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.69) EPS.

Separately, StockNews.com began coverage on FibroGen in a research note on Friday, March 14th. They set a “hold” rating for the company.

FibroGen Price Performance

NASDAQ:FGEN opened at $0.36 on Thursday. The company has a market capitalization of $36.05 million, a P/E ratio of -0.29 and a beta of 0.82. The business has a fifty day simple moving average of $0.50 and a two-hundred day simple moving average of $0.43. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). The company had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. lifted its position in shares of FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of FibroGen by 80.4% during the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock valued at $719,000 after purchasing an additional 605,572 shares during the period. Mackenzie Financial Corp raised its stake in shares of FibroGen by 416.6% during the 4th quarter. Mackenzie Financial Corp now owns 546,959 shares of the biopharmaceutical company’s stock valued at $290,000 after purchasing an additional 441,083 shares during the period. Squarepoint Ops LLC bought a new position in FibroGen in the 4th quarter worth about $205,000. Finally, Two Sigma Advisers LP grew its holdings in FibroGen by 18.3% during the 4th quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock valued at $465,000 after buying an additional 135,600 shares in the last quarter. 72.71% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.